SCHEMBL29889093

SCHEMBL29889093

CC(C)CCON=O.CCC(C)CON=O

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.69
KMT2A Q03164 1/20 0.34
ESR1 P03372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25269041 0.85
SCHEMBL2015595 0.85
SCHEMBL1330919 0.83
SCHEMBL23785 0.83
SCHEMBL22878567 0.81
SCHEMBL6368222 0.81
Hydrochloric Acid SCHEMBL8669936 0.81
Nitrogen SCHEMBL15994321 0.79 ALDH1A1 (0.90) ALDH1A1KMT2AESR1
Methyl Alcohol SCHEMBL28312507 0.79 ALDH1A1 (0.90) ALDH1A1KMT2AESR1
Nitrous Acid SCHEMBL14660251 0.77 ALDH1A1 (0.86) ALDH1A1KMT2AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240285549-A1 CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF CONSTANCE THERAPEUTICS, INC. (US) 2024-08-29 US disclosed
US-20240033312-A1 CANNABIS OIL EXTRACTS AND COMPOSITIONS CONSTANCE THERAPEUTICS, INC. (US) 2024-02-01 US disclosed
US-11596618-B2 Oral cannabinoid delivery formulations with mouthfeel experience enhancers Resurgent Biosciences, Inc. (US) 2023-03-07 US disclosed
US-20220331344-A1 ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS CHICAGO ATLANTIC ADMIN, LLC 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240033312-A1 CANNABIS OIL EXTRACTS AND COMPOSITIONS CNR2, CNR1, DNER ALDH1A1 1885/4885KMT2A 3448/4885ESR1 784/4885
US-20240285549-A1 CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF CNR1, CNR2, PROC ALDH1A1 1486/4885KMT2A 3580/4885ESR1 1107/4885
US-20220331344-A1 ORAL FORMULATIONS OF PSYCHOTROPIC MACROFUNGUS BOTANICAL EXTRACTS WITH MOUTHFEEL EXPERIENCE ENHANCERS MB, MLEC, NISCH ALDH1A1 3594/4885KMT2A 4605/4885ESR1 4415/4885
US-11596618-B2 Oral cannabinoid delivery formulations with mouthfeel experience enhancers CNR2, CNR1, CPNE4 ALDH1A1 4869/4885KMT2A 2218/4885ESR1 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.